Gelesis raises $16 million
Gelesis Inc., a Boston-based developer of obesity therapeutics, has raised $16 million in its first round of institutional funding.
Aeterna Zentaris Inc. said Thursday that it has deal to raise US$15 million in a registered direct offering.